The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

The model, which is predominantly based on genetic gain- or loss-of-function studies, implies that RAS is locked into an active state in cancer and engages various effector proteins to regulate ...

RAS genes constitute the most regularly mutated oncogene family in cancer. Indeed, RAS genes constituted the most regularly mutated oncogenes in the top three causes of cancer deaths in the US in ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Immune complexes, like the inflammasome, help protect stem cells from cancer by removing surface receptors and suppressing ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Scientists hope that new anti-oncogenic drugs designed to inhibit the growth-inducing signals produced by the RAS oncogene could stop cancer cells in the breast, colon, pancreas, and lung in their ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...